1 Safe-and-Steady Stock with Promising Prospects and 2 We Ignore

1 Safe-and-Steady Stock with Promising Prospects and 2 We Ignore

1 Safe-and-Steady Stock with Promising Prospects and 2 We Ignore

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Finding the right balance between safety and returns isn’t easy, which is why StockStory is here to help. Keeping that in mind, here is one low-volatility stock providing safe-and-steady growth and two that may not deliver the returns you need.




Rolling One-Year Beta: 0.15

Pioneering a unique business model in the pharmaceutical industry since 1996, Royalty Pharma (NASDAQ:RPRX) acquires rights to receive portions of sales from successful biopharmaceutical products, providing funding to drug developers without conducting research itself.

Why Are We Hesitant About RPRX?


  1. Products and services are facing significant end-market challenges during this cycle as sales have declined by 1.2% annually over the last two years

  2. Subscale operations are evident in its revenue base of $2.31 billion, meaning it has fewer distribution channels than its larger rivals

Royalty Pharma’s stock price of $36.30 implies a valuation ratio of 7.1x forward P/E. Read our free research report to see why you should think twice about including RPRX in your portfolio, it’s free.


Rolling One-Year Beta: 0.69

As one of the largest business development companies in the United States with over $20 billion in assets, Ares Capital (NASDAQ:ARCC) is a business development company that provides financing solutions to middle-market companies, primarily through direct loans and equity investments.


Why Should You Sell ARCC?

  1. Performance over the past two years shows its incremental sales were much less profitable, as its earnings per share fell by 3.6% annually

At $21.17 per share, Ares Capital trades at 10.5x forward P/E. Dive into our free research report to see why there are better opportunities than ARCC.



Rolling One-Year Beta: 0.93

Operating a global network of over 47,000 ATMs and 821,000 point-of-sale terminals across more than 60 countries, Euronet Worldwide (NASDAQ:EEFT) provides electronic payment solutions including ATM services, prepaid product processing, and international money transfer services.


Why Could EEFT Be a Winner?

  1. Annual revenue growth of 9.8% over the last five years was above the sector average and underscores its products and services value to customers

  2. Share repurchases have increased shareholder returns as its annual earnings per share growth of 11.9% exceeded its revenue gains over the last two years

  3. Market-beating return on equity illustrates that management has a knack for investing in profitable ventures